FDA-APPROVED

PT-141 (Bremelanotide)

The only FDA-approved drug for low sexual desire in women. Sold as Vyleesi. Acts on the brain's melanocortin system, not on blood flow, so it works very differently from Viagra.

The 30-second read

PT-141, sold as Vyleesi, is a small peptide that activates melanocortin receptors in the brain involved in sexual arousal. It was FDA-approved in 2019 for hypoactive sexual desire disorder (HSDD) in premenopausal women, the only drug FDA-approved specifically for that. It's used on demand: a small subcutaneous injection 45 minutes before activity, not a daily medication. Off-label use exists in men, including in research-peptide circles, where it's discussed for erectile-function issues that don't respond to PDE5 inhibitors like Viagra. Side effects can be real (nausea is common, transient blood-pressure increases are documented), and the response is variable. Real, FDA-reviewed evidence in the approved indication; off-label use sits on much thinner evidence.

Why this peptide is on people's radar

For a long time, "low sexual desire" wasn't really treated as a medical condition with options. Viagra and Cialis improved blood flow but didn't help with the part of the picture that happens before arousal, the desire itself. PT-141 was the first drug to come at that side of the equation pharmacologically. It activates melanocortin receptors in the central nervous system that are involved in sexual response, a completely different mechanism from the PDE5 inhibitors used for erectile dysfunction.

The FDA approved bremelanotide as Vyleesi in 2019 for hypoactive sexual desire disorder in premenopausal women, making it the second drug ever approved for that indication and the only one used on-demand. Sales have been modest compared to the male-ED drugs, partly because the experience is different, the drug works for some people, less so for others, and the side-effect profile (especially nausea) is real.

The off-label conversation is bigger than the on-label one. Men with erectile-function issues that don't respond to PDE5 inhibitors sometimes turn to PT-141 because the mechanism is different. Research-peptide circles discuss it for both desire and arousal in either sex. None of those off-label uses are FDA-reviewed.

What people are usually trying to do with it

People exploring PT-141 are usually looking for:

  • Help with low sexual desire that's been distressing, the FDA-approved use case
  • An option for erectile-function issues that haven't responded to Viagra-class drugs (off-label)
  • Something that works on desire, not just blood flow
  • An on-demand option rather than a daily medication
  • An alternative if testosterone or other hormone interventions haven't been the right fit

What the science actually shows

PT-141 has more rigorous human evidence than most peptides on this site. Plain-English summary:

HSDD in premenopausal women (FDA-approved)

Two large Phase 3 trials (RECONNECT) showed statistically significant improvements in sexual desire and reductions in distress related to low desire. The effect size is modest but real, and reproducible across both trials.12

Erectile function (off-label, men)

Earlier-stage trials in men with erectile dysfunction showed signals of efficacy, including in some men who had not responded to PDE5 inhibitors. Development for the male ED indication did not advance, partly because of side effects at the doses studied.3

Mechanism, not a vascular drug

PT-141 acts on melanocortin receptors (MC3R and MC4R) in the brain. This is fundamentally different from Viagra-class drugs, which work on blood-flow signaling. The pathway involves dopamine and oxytocin release in arousal-related brain regions.4

Blood pressure considerations

PT-141 produces transient increases in blood pressure (typically a few hours after dosing). For most people this is clinically minor; for people with uncontrolled hypertension it's a meaningful contraindication.5

What it has not been shown to do

Reliably treat erectile dysfunction (the development program for that indication didn't advance). Be FDA-approved for any use in men. Improve sexual function in postmenopausal women (the Vyleesi indication is specifically premenopausal). Substitute for relationship and psychosocial factors that contribute to sexual concerns.

The honest read

What's solid:

For HSDD in premenopausal women, this is FDA-approved on the basis of two Phase 3 trials. The mechanism is well-characterized. The on-demand dosing approach is clinically reasonable. For people who fit the indication, it's a real option.

What's still being worked out:

Who responds and who doesn't, the trial-level effect size is real but variable across individuals. Whether the male ED use case can be revisited at lower doses or with different patient selection. Long-term outcomes when used regularly over time. Postmenopausal use isn't part of the approval and hasn't been studied as rigorously.

What's hyped beyond the evidence:

Framing PT-141 as a more effective Viagra. The trial data for the female-HSDD indication shows modest mean improvements with significant individual variability, not dramatic universal effects. Off-label male use is supported by anecdote and earlier-stage trials, not by rigorous, FDA-reviewed evidence. Side effects (nausea especially) are common enough that not everyone tolerates it well.

Things to know if you're looking into it

  • How it's used: on-demand subcutaneous injection (auto-injector pen) about 45 minutes before sexual activity. Not a daily medication.
  • Approved use: Vyleesi for hypoactive sexual desire disorder in premenopausal women, FDA-approved in 2019.
  • Common side effects: nausea is the most common, particularly the first few uses; flushing, headache, and transient blood-pressure increases also occur. Skin darkening can occur with frequent use due to melanocortin pathway involvement.
  • Don't use more than once in 24 hours: the label limits to one dose per 24-hour period and no more than 8 doses per month.
  • Blood pressure caveat: contraindicated in uncontrolled hypertension or known cardiovascular disease. Transient increases in blood pressure occur after dosing.
  • Off-label use: discussed in research-peptide circles and by some clinicians for male ED and other indications. None of those off-label uses are FDA-reviewed; involve a clinician.
  • Specific dosing schedule, mechanism, half-life, and trial detail: all in the "Want to go deeper?" section below.

Reconstitution & dose calculator

FDA-approved as Vyleesi® for HSDD in premenopausal women. The approved Vyleesi product is a pre-dosed 1.75 mg auto-injector pen and doesn't require reconstitution. The calculator below covers research-peptide lyophilized PT-141, which circulates outside the FDA-approved channel for off-label use (most commonly in men for ED-related applications, despite the FDA approval being narrow). Same molecule, different supply chain. Episodic / as-needed use, not daily — max 1 dose per 24 hours, max 8 doses per month per the FDA label. This is an educational reference, not dosing guidance.
Suggested start
1 mg/dose
Below FDA dose; assess for nausea before scaling
FDA-approved dose
1.75 mg/dose
Vyleesi label dose for women with HSDD
Max dose
2 mg/dose
Above 2 mg, side-effect risk grows without added benefit
Frequency limits
1 / 24h
Max 8 doses / month per FDA label
mL
Defaults to 5 mg/mL (2 mL into the 10 mg vial), the standard community reconstitution. The FDA-approved Vyleesi 1.75 mg dose lands at exactly 35 syringe units at this concentration. For better small-dose precision (if starting at 1 mg or below to assess tolerance), reconstitute with 4 mL water (2.5 mg/mL) and the units roughly double.
mg
Subcutaneous injection, 45+ minutes before anticipated sexual activity. Not a daily medication. The FDA limit is 1 dose per 24 hours and 8 doses per month — this isn't a "use it more often for better results" drug. Effects last for hours; multiple doses don't compound benefit.
Concentration
5.0 mg/mL
Per dose
0.35 mL
35 units on insulin syringe
Doses per vial
~5
~5 doses available (use as-needed)

When to stay put vs. adjust — PT-141 is episodic, not titrated

Start at 1 mg, not 1.75 mg, for the first dose. Nausea is the most common acute side effect across the melanocortin-agonist class, and PT-141 specifically is known for first-dose GI effects in many users. The Vyleesi label dose (1.75 mg) is appropriate for most users once tolerance is established, but the first dose is the worst window for nausea. Starting low lets you confirm you can tolerate the dose without ruining the experience you're dosing for.

If 1 mg was tolerated, step to 1.75 mg for subsequent doses. The FDA-approved dose is where the trial data sits and where most users get the best balance of effect and tolerability. Going above 1.75 mg doesn't reliably produce more effect — the receptor pharmacology saturates around the approved dose, and side effects continue to scale.

Inject 45+ minutes before activity. PT-141 is not a fast-acting drug. The peptide needs time to cross into the central nervous system and reach the melanocortin receptors that drive the effect. Injecting too close to anticipated activity means the effect arrives late or not at all.

Eat first. The single most-reported way to reduce PT-141 nausea is dosing on a full stomach. Empty-stomach injection is the most common reason users describe a "miserable" first experience.

Don't dose more than once in 24 hours. The FDA label is explicit on this and it's grounded in the trial pharmacokinetics. Multiple doses in a 24-hour window don't add effect; they just stack side effects (nausea, BP elevation, headache).

Don't exceed 8 doses per month. Beyond the per-dose tolerability question, the cumulative-exposure question for chronic frequent use isn't well-characterized. The melanocortin-pathway skin-darkening effect (separate from MT-2's tanning use) starts to become noticeable with frequent use.

Hard contraindications: uncontrolled hypertension or known cardiovascular disease (PT-141 produces transient blood-pressure elevation), pregnancy or trying to conceive, current cardiovascular event recovery, severe hepatic or renal impairment. The BP-elevation effect is well-documented in the FDA-approval program and is the safety signal that led to the cardiovascular contraindications.

The honest read. PT-141 is unusual in this catalog for being both FDA-approved and useful for an indication beyond what the approval covers. The Vyleesi label is narrow (premenopausal women with HSDD), but the molecular mechanism (central melanocortin agonism that increases sexual desire and arousal) applies to anyone with that receptor system. That's why off-label use in men is widespread and why the research-peptide lyophilized form continues to circulate. The trial data behind the FDA approval is real, the dose math is well-characterized, and the safety profile is moderate — nausea is the dominant complaint, BP elevation is the main contraindication driver, and the per-dose limits exist for good pharmacokinetic reasons. Different shape than most peptides on this site: the question with PT-141 isn't "does it work" (it does, for the receptor system) but "is the use case yours" (the approval is narrow, off-label use is wide).

For educational and research purposes only. This is not medical advice. The FDA-approved form of PT-141 is Vyleesi® (bremelanotide), a pre-dosed 1.75 mg auto-injector for hypoactive sexual desire disorder in premenopausal women. Off-label use exists outside that indication. PT-141 produces transient blood-pressure elevation; uncontrolled hypertension and known cardiovascular disease are contraindications. Consult a licensed healthcare provider before any health decision.

What people often ask

How is PT-141 different from Viagra?

Different mechanism entirely. Viagra works on blood-flow signaling in the genitals. PT-141 acts on melanocortin receptors in the brain involved in sexual desire and arousal. People who don't respond to Viagra sometimes respond to PT-141 because the targets are completely different.

Is it FDA-approved for men?

No. The FDA approval (Vyleesi, 2019) is for premenopausal women with hypoactive sexual desire disorder. Off-label use in men exists but is not FDA-reviewed.

How much does it actually help?

In trials, the average improvement in desire was statistically significant but modest. Some women had meaningful responses; some had little to none. Individual variation is large.

What about nausea?

Common, about 40% of women in trials reported nausea, especially with the first dose. It tends to become less prominent with repeated use, but it's the main reason people stop.

Does it cause skin darkening?

Yes, with frequent use. PT-141 acts on melanocortin receptors, which include MC1R, the receptor involved in melanin production. About 1% of trial users developed focal hyperpigmentation, often on the face, gums, or breasts. It usually fades when the drug is stopped.

Can it be used with Viagra or Cialis?

The combination hasn't been formally studied. Both drugs can affect blood pressure and using them together raises that combined cardiovascular concern. Anyone considering this should involve a clinician.

How quickly does it work?

The label says administer 45 minutes before sexual activity. Effects last several hours. Some people report onset earlier or later than the 45-minute window.

FDA and regulatory status

Status as of May 5, 2026: FDA-approved as Vyleesi (June 2019) for hypoactive sexual desire disorder (HSDD) in premenopausal women. Manufactured by AMAG Pharmaceuticals (later Palatin Technologies licensing). Approved as an on-demand subcutaneous injection. Not approved for any indication in men. Status updates land here when they happen.

Want to go deeper? Mechanism, dosing schedule, half-life, the RECONNECT trial detail, side-effect profile, and references. Click to expand.

Background and development

PT-141 (bremelanotide) is a synthetic cyclic heptapeptide and a metabolite of melanotan II. It was initially developed by Palatin Technologies as a potential treatment for sexual dysfunction in both men and women. Early development for male erectile dysfunction did not advance, but the female HSDD indication produced positive Phase 3 results in the RECONNECT program. FDA-approved as Vyleesi in June 2019.

Mechanism of action

Bremelanotide is a non-selective agonist at melanocortin receptors, with predominant activity at MC3R and MC4R, which are concentrated in arousal-related regions of the central nervous system (hypothalamus and limbic structures). Activation of these receptors triggers downstream dopamine and oxytocin release in pathways involved in sexual desire and arousal. Unlike PDE5 inhibitors, the mechanism does not involve vasodilation or local blood-flow signaling.

Half-life

Plasma half-life is approximately 2.7 hours. The clinically relevant window for sexual activity is roughly 1 to 8 hours after dosing.

FDA-approved dosing

This is a prescription medication. Dosing is established by your prescriber.

Vyleesi label: 1.75 mg subcutaneous injection (single-use auto-injector) at least 45 minutes before anticipated sexual activity. Not more than one dose in 24 hours, not more than 8 doses per month.

The RECONNECT Phase 3 trials

Two identically designed Phase 3 trials enrolled premenopausal women with acquired, generalized HSDD. Both trials reported statistically significant improvements in desire (FSFI desire subscale) and reductions in distress related to low desire (FSDS-DAO Item 13), measured against placebo. The effect sizes were modest but reproducible across both trials, supporting the FDA approval.

Side effects and safety profile

Reported in trials and post-marketing surveillance:

  • Nausea, most common (~40% of users), often most prominent with the first dose
  • Flushing, common
  • Headache, common
  • Injection-site reactions, common
  • Transient blood-pressure increases, documented and the basis of the cardiovascular contraindications
  • Focal hyperpigmentation, less common (~1% of trial users); typically fades after discontinuation

Contraindicated in uncontrolled hypertension and known cardiovascular disease. Use cautiously in patients with risk factors for cardiovascular disease.

References

  1. Kingsberg SA, Clayton AH, Portman D, et al. (2019). "Bremelanotide for the treatment of hypoactive sexual desire disorder: two randomized phase 3 trials (RECONNECT)." Obstet Gynecol, 134(5), 899–908. PubMed
  2. Simon JA, Kingsberg SA, Portman D, et al. (2019). "Long-term safety and efficacy of bremelanotide in HSDD." Obstet Gynecol, 134(5), 909–917. PubMed
  3. Diamond LE, Earle DC, Rosen RC, et al. (2004). "Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction." Int J Impot Res, 16(1), 51–59. PubMed
  4. Pfaus JG, Shadiack A, Van Soest T, et al. (2004). "Selective facilitation of sexual solicitation in the female rat by a melanocortin receptor agonist." Proc Natl Acad Sci USA, 101(27), 10201–10204. PubMed
  5. U.S. Food and Drug Administration. "Vyleesi Prescribing Information." FDA.gov
For educational and research purposes only. This is not medical advice. PT-141 (Vyleesi) is a prescription medication. Off-label use is at the discretion of a licensed prescriber. PeptideLibraryHub is independent and does not sell peptides or accept money from anyone who does. Information current as of May 2026.